Cannabis Science Releases Operations Guidance On New Medicinal Cannabis Commercialization Deals

DENVER--(BUSINESS WIRE)-- Cannabis Science, Inc. (OTCBB: CBIS), a US biotech company developing pharmaceutical cannabis products, is pleased to provide investor guidance on its previously announced Medicinal Cannabis Commercialization negotiations and current operational structures. Currently, Cannabis Science has some outstanding business opportunities in the final stages of closing. It anticipates announcing the first one within the next week. Some of these new deals are designed to bring its anti-cancer cannabis formulations and its other critical ailment formulations to the public through the FDA in the USA and more rapidly through other expanded markets around the world.

One of the larger deals the company expects to sign and announce within the next few days is a business relationship with a multi-million dollar pharmaceutical technology provider. Under the terms of the agreement, Cannabis Science will work closely with the technology provider to market and sell their co-branded products on an exclusive and non-exclusive basis with this new ground breaking technology in the Medical Cannabis industry. Cannabis Science sees this as an incredible opportunity to participate in an exciting growing technology company while at the same time advancing its medical marijuana medicine market and development.

The Company is in advanced stages of negotiations to contract for a joint-marketing program that will provide cancer patients with proprietary medical marijuana formulations for cancer treatment. According to the World Health Organization, 12 million cancer deaths are likely to occur worldwide by 2030. With the $47.7 billion cancer drug market projected to grow significantly over the coming decades, Cannabis Science is committed and focused on positioning itself as a key player in the medical cannabis cancer treatment sector.

Robert Melamede, Ph.D. and Cannabis Science CEO said, “We appreciate the dedication and patience that many of our investors have shown. We have been working diligently to provide a path in the complicated legal and regulatory environment that surrounds the medical cannabis industry that will benefit our shareholders and the countless people in need around the world who have been deprived of the health promoting benefits provided by this unique plant. These commercialization agreements will give us an opportunity to generate significant revenues for Cannabis Science We provide a further update and agreement details in the coming weeks as these commercial agreements are signed.”

About Cannabis Science, Inc.

Cannabis Science, Inc. is at the forefront of pharmaceutical grade medical marijuana research and development. The Company works with world authorities on phytocannabinoid science targeting critical illnesses, and adheres to scientific methodologies to develop, produce and commercialize phytocannabinoid-based pharmaceutical products. In sum, we are dedicated to the creation of cannabis-based medicines, both with and without psychoactive properties, to treat disease and the symptoms of disease, as well as for general health maintenance.

Forward Looking Statements

Forward Looking Statements; This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. A statement containing works such as "anticipate," "seek," intend," "believe," "plan," "estimate," "expect," "project," "plan," or similar phrases may be deemed "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the Company's reliance on existing regulations regarding the use and development of cannabis-based drugs. Cannabis Science, Inc. does not undertake any duty nor does it intend to update the results of these forward-looking statements.



CONTACT:

Cannabis Science Inc.
Dr. Robert J. Melamede,President & CEO
1-888-889-0888
[email protected]
www.cannabisscience.com

KEYWORDS:   United States  North America  California  Colorado

INDUSTRY KEYWORDS:   Public Policy/Government  Healthcare Reform  Research  Science

MEDIA:

Suggested Articles

The profit margins and management of Community Health Group raise questions about oversight of managed care insurers.

Financial experts are warning practices about the pitfalls of promoting medical credit cards to their patients.

A proposed rule issued by HHS on Tuesday would expand short-term coverage, a move Seema Verma said will have "virtually no impact" on ACA premiums.